Entering text into the input field will update the search result below

Endocyte Q3

Nov. 07, 2018 4:07 PM ETEndocyte, Inc. (ECYT) StockBy: Douglas W. House, SA News Editor
  • Endocyte (NASDAQ:ECYT) Q3 results ($M): Net loss: (23.3) ( -84.9%).
  • Upcoming milestones:
  • IND for Phase 1 study of EC17/CAR-T therapy in osteosarcoma (this quarter).
  • Completion of merger with Novartis (NVS): H1 2019.
  • Analysis of rPFS in VISION study: late 2019.

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
ECYT--
Endocyte, Inc.